Use of low-dose, weekly carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).

被引：2
|
作者：
O'Leary-Kelly, Meghan
Gao, Dexiang
Weisdack, Sarah
Lam, Elaine Tat
Bernard, Brandon David
Flaig, Thomas W.
Kessler, Elizabeth Riley
机构：
[1] Univ Colorado Canc Ctr, Aurora, CO USA
[2] Univ Colorado Denver, Aurora, CO USA
[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[4] Univ Colorado Comprehens Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.331
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
331
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [2] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
  • [3] High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).
    Chen, Julia
    Joshua, Anthony M.
    Denmeade, Samuel R.
    Antonarakis, Emmanuel S.
    Crumbaker, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).
    Kohli, Manish
    Huang, Xiaoyi
    Yuan, Tiezheng
    Sun, Zhifu
    Costello, Brian Addis
    Quevedo, Fernando
    Tan, Winston
    Nandy, Debashis
    Longenbach, Sherri
    Wang, Liang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [5] Retreatment of Men With Metastatic Castrate-Resistant Prostate Cancer With Abiraterone
    Leibowitz-Amit, Raya
    Alimohamed, Nimira
    Vera-Badillo, Francisco E.
    Seah, Jo-An
    Templeton, Arnoud J.
    Knox, Jennifer J.
    Tannock, Ian F.
    Sridhar, Srikala S.
    Joshua, Anthony M.
    PROSTATE, 2014, 74 (14): : 1462 - 1464
  • [6] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
    Moses, Marcus Marie
    Ledet, Elisa
    Manogue, Charlotte
    Lewis, Brian E.
    Barata, Pedro C.
    Sartor, A. Oliver
    Layton, Jodi Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Metastatic castrate-resistant prostate cancer
    Schellhammer, Paul
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) : 51 - 52
  • [9] The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Gupta, S.
    Yang, Q.
    Halabi, S.
    Tubbs, A.
    Gore, Y.
    George, D. J.
    Nanus, D. M.
    Antonarakis, E. S.
    Danila, D.
    Szmulewitz, R.
    Wenstrup, R. J.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1165 - S1166
  • [10] Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
    Horgan, Anne M.
    Seruga, Bostjan
    Pond, Greg R.
    Alibhai, Shabbir M.
    Amir, Eitan
    De Wit, Ronald
    Eisenberger, Mario A.
    Tannock, Ian F.
    JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (02) : 119 - 126
12345